<DOC>
	<DOC>NCT00619710</DOC>
	<brief_summary>The purpose of this study is to demonstrate the non-inferiority of meropenem (Merrem) and imipenem in hospitalised subjects with complicated skin and skin structure infections.</brief_summary>
	<brief_title>Complicated Skin and Skin Structure Infections</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Abscess</mesh_term>
	<mesh_term>Cellulitis</mesh_term>
	<mesh_term>Skin Diseases, Infectious</mesh_term>
	<mesh_term>Meropenem</mesh_term>
	<mesh_term>Thienamycins</mesh_term>
	<mesh_term>Imipenem</mesh_term>
	<mesh_term>Cilastatin</mesh_term>
	<criteria>Subjects are hospitalized males and females, aged 13 years or older, with clinical evidence of complicated skin and skin structure bacterial infection with material suitable for culture from 1 primary site of infections Within 72 hours before enrollment or at the time of enrollment, all subjects must provide an appropriate specimen for culture and susceptibility testing Subjects who have been given prior antibacterial therapy within 14 days of trial entry may be entered only if a culture is obtained showing persistence of a pathogen in blood or at the site of infection Subjects with a known or suspected hypersensitivity to cephalosporins, penicillins, or carbapenems Subjects with a history of seizure disorders or subjects currently receiving antiepileptic medication Subjects with underlying infections or conditions which would interfere with evaluation of this study</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2008</verification_date>
	<keyword>skin infections</keyword>
	<keyword>MERREM</keyword>
	<keyword>PRIMAXIN IV</keyword>
	<keyword>complex abscess</keyword>
	<keyword>perirectal abscess</keyword>
	<keyword>wound infections</keyword>
	<keyword>infected ischemic/diabetic ulcers</keyword>
	<keyword>cellulitis</keyword>
	<keyword>Meropenem</keyword>
	<keyword>Imipenem-cilastatin</keyword>
</DOC>